文献速递淋巴瘤

韩国弥漫大B细胞淋巴瘤LymphGen亚型分布及预后影响

Distribution and prognostic impact of LymphGen subtypes in Korean diffuse large B-cell lymphoma using clinical NGS panel.
PubMed 文献 · Blood Adv · 2026-01-01

该研究使用院内开发的121基因靶向NGS panel对韩国DLBCL患者进行LymphGen分类,并评估拷贝数可靠性和与外部参考数据的基准性能。DLBCL-NOS中MCD亚型占比最高(25.2%),且较西方队列显著更常见;MCD、BN2和A53亚型经R-CHOP治疗的总生存较差,尤其在MYC/BCL2双表达患者中。

要点

  • 韩国DLBCL-NOS中MCD亚型占25.2%,显著高于西方队列。
  • MCD亚型倾向于非GCB型和MYC/BCL2双表达DLBCL。
  • R-CHOP治疗的MCD、BN2、A53亚型总生存较差,尤其在双表达患者中。

核心结论

  • 使用临床可用的NGS panel成功实施LymphGen分类,揭示韩国DLBCL独特遗传格局。
  • LymphGen有助于识别高危亚组,为预后分层和治疗优化提供依据。

研究设计与样本

  • 研究采用机构开发的121基因靶向NGS panel对韩国DLBCL患者进行LymphGen分类。
  • 评估了质量控制指标、拷贝数可靠性,并与MSK-IMPACT外部参考数据集进行基准比较。
  • DLBCL-NOS患者n=123,原发中枢神经系统DLBCL患者n=77。

主要发现

  • DLBCL-NOS(n=123)亚型分布:MCD 25.2%、A53 14.6%、ST2 7.3%、BN2 5.7%、EZB 3.3%、复合EZB/ST2 1.6%、其他42.3%。
  • 原发CNS DLBCL(n=77)亚型分布:MCD 70.1%、复合MCD/A53 2.6%、A53 3.9%、BN2 2.6%、ST2 1.3%、EZB 1.3%、其他18.2%。
  • 与西方队列相比,韩国DLBCL-NOS队列MCD亚型显著更常见。
  • MCD亚型倾向于非GCB型DLBCL和MYC/BCL2双表达DLBCL。
  • R-CHOP治疗的DLBCL-NOS中,MCD、BN2和A53亚型总生存较EZB和ST2差,尤其在MYC/BCL2双表达患者中。

临床怎么用

  • 可采用临床可用的靶向NGS panel进行LymphGen分类以识别高危DLBCL亚组。
  • MCD、BN2和A53亚型患者,尤其合并MYC/BCL2双表达时,预后较差,需考虑更积极治疗策略。

局限性

  • 需要在多样人群和真实世界临床环境中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Several molecular subclassifications of diffuse large B-cell lymphoma (DLBCL) with prognostic and therapeutic potential have been proposed; however, validation in diverse populations and real-world clinical settings remains limited. We investigated the genetic subtypes of Korean DLBCL using the LymphGen classifier and an institutionally developed 121-gene targeted next-generation sequencing (NGS) panel. We also assessed quality control metrics, copy number reliability, and benchmarking performance against an external reference data set (Memorial Sloan Kettering Cancer Center-Integrated Mutation Profiling Actionable Cancer Targets). LymphGen subtypes differed by entity. Patients with DLBCL, not otherwise specified (DLBCL-NOS; n = 123) were classified as MCD (25.2%), A53 (14.6%), ST2 (7.3%), BN2 (5.7%), EZB (3.3%), composite EZB/ST2 (1.6%), and unclassified ("other"; 42.3%). Patients with primary DLBCLs of the central nervous system (n = 77) were classified as MCD (70.1%), composite MCD/A53 (2.6%), A53 (3.9%), BN2 (2.6%), ST2 (1.3%), EZB (1.3%), and "other" (18.2%). Compared with Western cohorts, the LymphGen subtype distribution in our Korean DLBCL-NOS cohort differed notably, with MCD being significantly more prevalent. The MCD subtype tended to be associated with non-germinal center B-cell-like DLBCL and DLBCL with MYC/BCL2 double expression (DE). In R-CHOP (rituximab, cyclophosphamide, doxorubicin, Oncovin [vincristine], and prednisone)-treated DLBCL-NOS, patients with MCD, BN2, and A53 subtypes had poorer overall survival than those with EZB and ST2, particularly among patients with concurrent MYC/BCL2 DE. Using a clinically applicable NGS panel, we successfully implemented the LymphGen classification system. This study underscores the distinct genetic landscape of Korean DLBCL and highlights the utility of LymphGen in identifying high-risk subgroups, providing a basis for prognostic stratification and therapeutic optimization.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Yim J, Lee S, Kim S, et al. Distribution and prognostic impact of LymphGen subtypes in Korean diffuse large B-cell lymphoma using clinical NGS panel. Blood Adv. 2026. PMID: 41544233. doi:10.1182/bloodadvances.2025017049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。